Portfolio

/Portfolio
Portfolio2018-09-05T18:11:54+00:00

TAI Diagnostics

Monitoring the Health of Transplanted Organs

TAI Diagnostics, Inc. is a biotechnology company focused on providing a non-invasive and highly sensitive diagnostic test to monitor the health of transplanted organs in patients who have received solid organ transplants.

Rejection is the major cause of transplant failure, and transplant recipients require lifelong rejection surveillance to guide modulation of immunosuppressant dosage and frequently require clinical interventions to improve organ function.

TAI Diagnostics first test offering, myTAIHEART, is for cardiac transplant patients. The current gold standard surveillance test for these patients is the endomyocardial biopsy, a procedure that is invasive, subject to sampling error, and expensive for both the patient and the healthcare system.

myTAIHEART was designed to meet these clinical needs. The assay requires only a small blood sample and is available to adult and pediatric patients rapidly post-transplant. The myTAIHEART Assay has a high degree of sensitivity and specificity, a rapid turnaround time, and can be offered at a very competitive price point.

LEARN MORE

Interested in Learning More?

To learn more about 30Ventures, contact us today

Contact Us